miR-520a-3p regulates the signaling pathway of cytokine secretion in cervical cancer

doi:10.12047/j.cjap.5935.2020.073

Abstract

Abstract: Objective: To investigate the molecular mechanism of miR-520a-3p regulating the secretion of cytokines in cervical cancer. Methods: The matching between miR-520a-3p and the NF-κB complex subunit RELA was analyzed by TargetScanHuman, and then the luciferase reporting system was used to detect whether miR-520a-3p targeted the NF-κB complex subunit RELA. After cervical cancer HELA cells stimulated by LPS, in the overexpression group or the knockout group, miR-520a-3p mimics or inhibitor were mixed with transfection reagent and dripped into HELA cells. The expression levels of colony stimulating factor (GCSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 19 (IL-9), interleukin 10 (IL-10), interleukin 12 p40 (IL-12 p40), interleukin 12 p70 (IL-12 p70), interleukin 13 (IL-13), interleukin 17 (IL-17), interferon gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-5 (MCP-5), small inducible cytokine A5 (RANTES), tumor necrosis factor-alpha (TNFα) were detected by enzyme-linked immunosorbent assay in both the overexpression group and the knockout group. Each experiment was repeated three times. Results: miR-520a-3p targeted the 3’UTR of RELA. After activation of the NF-κB signaling pathway by lipopolysaccharide (LPS), the protein expression levels of cytokines GCSF, GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-17, IFN-γ, MCP-1, MCP-5, RANTES, TNFα secreted by HELA cells of cervical cancer were increased significantly (P＜0.05). In the overexpression group, the protein expression level of RELA of NF-κB complex subunit was decreased, and the protein expression level of the above-mentioned cytokines secreted by HELA cells of cervical cancer were decreased (P＜0.05). In the knockdown group, the protein expression level of RELA, a subunit of NF-κB complex, and the protein expression level of the above-mentioned cytokines secreted by HELA cells of cervical cancer were increased (P＜0.05). Conclusion: miR-520a-3p inhibits cytokine secretion in HELA cells of cervical cancer by targeting RELA, a key molecule in the NF-κB signaling pathway.

Key words: miR-520a-3p, NF-κB, HELA cells of cervical cancer, cytokines

CLC Number:

R737.3

LIU Hong-yan, LU Qi-hong, HUANG Chu-ying. miR-520a-3p regulates the signaling pathway of cytokine secretion in cervical cancer[J]. CJAP, 2020, 36(4): 340-345.

References

[1] Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline[J]. J Glob Oncol, 2017, 3(5): 635-657.
[2] Network TCGA. Integrated genomic and molecular characterization of cervicalcancer[J]. Nature, 2017, 543(7645): 378-384.
[3] Wang H, Zhou B, Cao J, et al. Pro-inflammatory cytokines are involved in fluoride-induced cytotoxic potential in HeLa cells[J]. Biol Trace Elem Res, 2017, 175(1): 98-102.
[4] Sun SC. The non-canonical NF-κB pathway in immunity and inflammation[J]. Nature Reviews Immunology, 2017, 17(9): 545.
[5] Zhang R, Liu R, Liu C, et al. A novel role for MiR-520a-3p in regulating EGFR expression in colorectal cancer[J]. Cell Physiol Biochem, 2017, 42(4): 1559-1574.
[6] Yu J, Tan Q, Deng B, et al. The microRNA-520a-3p inhibits proliferation, apoptosis and metastasis by targeting MAP3K2 in non-small cell lungcancer[J]. Am J Cancer Res, 2015, 5(2): 802-811.
[7] ZhuH, Zeng Y, Zhou CC, et al. SNHG16/miR-216-5p/ZEB1 signal pathway contributes to the tumorigenesis of cervical cancer cells[J]. Arch Biochem Biophys, 2018, 637(1): 1-8.
[8] Song B, Ding C, Chen W, et al. Incidence and mortality of cervical cancer in China, 2013[J]. Chin J Cancer Res, 2017, 29(6): 471-476.
[9] Zhang T, Jiao J, Jiao X, et al. Aberrant frequency of TNFR2+Treg and related cytokines in patients with CIN and cervical cancer:[J]. Oncotarget, 2018, 9(4): 5073-5083.
[10] Huang Q, Hong L, Tao C, et al. Regulator T cells and cytokines in peripheral blood of cervical cancer patients with different stages[J]. Lab Med, 2017, 32(9): 769-772.
[11] Lu A, Disoma C, Zhou Y, et al. Protein interactome of the deamidase phosphoribosylformylglycinamidine synthetase (PFAS) by LC-MS/MS[J]. Biochem Biophys Res Commun, 2019, 513(3): 746-752.
[12] Li J, Wei J, Mei Z, et al. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44[J]. Am J Transl Res, 2017, 9(1): 146.
[13] 方小霞, 周易, 孙高林, 等. TGF-β1对Aβ_(1-42)诱导海马神经元-小胶质细胞共培养体系中细胞因子表达和分泌的影响[J]. 中国应用生理学杂志, 2018, 34(5): 4-7.
[14] 李平, 张巧莲, 李双英. 卒中后抑郁与血清炎性细胞因子水平及神经功能损害的相关性分析[J]. 中国应用生理学杂志, 2017, 33(2): 121-123.
[15] Chen W, Qin Y, Liu S. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance[J]. Clin Transl Med, 2018, 7(1): 27.
[16] Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human pathobiology[J]. Cell, 2017, 168(1-2): 37-57.
[17] Bahls L, Yamakawa R, Zanao K, et al. Human leukocyte antigen class Ⅰ and class Ⅱ polymorphisms and serum cytokine profiles in cervical cancer[J]. Int J Mol Sci, 2017, 18(9): 1478.
[18] Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients[J]. Proc NatlAcad Sci U S A, 2017, 114(34): E7150.
[19] Deivendran S, Marzook KH, Pillai MR. The role of inflammation in cervical cancer[J]. Adv Exp Med Biol, 2014, 816: 377-399.
[20] Paradkar PH, Joshi JV, Mertia PN, et al. Role of cytokines in genesis, progression and prognosis of cervical cancer[J]. Asian Pac J Cancer Prev, 2014, 15(9): 3851-3864.
[21] Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16(3): 203-222.